ITRM Stock Price, Iterum Therapeutics plc Quote, Chart

Market Summary

USD1.53-0.01

Market Closed

-0.65%

ITRM Stock Price

View Fullscreen

ITRM RSI Chart

ITRM Valuation

Market Cap

25.1M

Price/Earnings (Trailing)

-0.65

Price/Sales (Trailing)

683.71

EV/EBITDA

-0.83

Price/Free Cashflow

-0.64

ITRM Price/Sales (Trailing)

ITRM Profitability

EBT Margin

-102048.65%

Return on Equity

599.27%

Return on Assets

-146.13%

Free Cashflow Yield

-156.54%

ITRM Fundamentals

ITRM Revenue

Revenue (TTM)

37.0K

ITRM Earnings

Earnings (TTM)

-38.4M

Earnings Growth (Yr)

-142.87%

Earnings Growth (Qtr)

-218.85%

Breaking Down ITRM Revenue

Last 7 days

-3.2%

Last 30 days

-0.6%

Last 90 days

-0.6%

Trailing 12 Months

31.9%

How does ITRM drawdown profile look like?

ITRM Financial Health

Current Ratio

1.89

Debt/Equity

-1.79

Debt/Cashflow

-3.43

ITRM Investor Care

Shares Dilution (1Y)

29.28%

Diluted EPS (TTM)

-2.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	715.0K	530.0K	276.0K	37.0K
2018	598.3K	688.5K	778.8K	869.0K
2017	0	0	0	508.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Iterum Therapeutics plc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 22, 2023	dunne michael w.	bought	35,000	1.4	25,000	-
Dec 18, 2023	dunne michael w.	bought	18,442	1.8442	10,000	-
Dec 01, 2023	puttagunta sailaja	sold (taxes)	-6,217	2.12	-2,933	chief medical officer
Dec 01, 2023	puttagunta sailaja	acquired	-	-	8,333	chief medical officer
Nov 22, 2023	dunne michael w.	bought	40,690	2.0345	20,000	-
Nov 20, 2023	fishman corey n.	bought	15,863	1.5863	10,000	chief executive officer
Oct 01, 2023	dunne michael w.	acquired	-	-	3,487	-
Oct 01, 2023	hunt ronald	acquired	-	-	5,479	-
Jul 01, 2023	dunne michael w.	acquired	-	-	1,779	-
Jul 01, 2023	hunt ronald	acquired	-	-	2,796	-

Which funds bought or sold ITRM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC	new	-	102	102	-%
Feb 14, 2024	New Leaf Venture Partners, L.L.C.	unchanged	-	113,588	191,255	0.15%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-63.21	-5,014	34,540	-%
Feb 14, 2024	Ancora Advisors LLC	unchanged	-	45.00	75.00	-%
Feb 14, 2024	Royal Bank of Canada	new	-	20,000	20,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-16,240	-	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	6.39	60,000	98,000	-%
Feb 13, 2024	HM PAYSON & CO	unchanged	-	3.00	6.00	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-60.72	-380	10,794	-%
Feb 13, 2024	Apollon Financial, LLC	new	-	394,000	394,000	0.16%

Are Funds Buying or Selling ITRM?

Are funds buying ITRM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ITRM

No. of Funds

Unveiling Iterum Therapeutics plc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 31, 2024	point72 asset management, l.p.	6.3%	850,000	SC 13G
Jan 03, 2022	sabby management, llc	12.%	0	SC 13G/A
Feb 12, 2021	new leaf venture management iii, l.l.c.	3.3%	3,911,583	SC 13D/A
Feb 12, 2021	sarissa capital management lp	0%	0	SC 13D/A
Feb 11, 2021	ra capital management, l.p.	0.0%	0	SC 13G/A
Feb 10, 2021	advent life sciences llp	3.4%	2,859,173	SC 13D/A
Feb 10, 2021	sabby management, llc	5.26%	7,750,000	SC 13G
Feb 09, 2021	pivotal bioventure partners fund i, l.p.	1.2%	945,085	SC 13G/A
Feb 08, 2021	ra capital management, l.p.	10.6%	13,730,376	SC 13G/A
Feb 03, 2021	canaan x l.p.	4.0%	1,733,170	SC 13G/A

Recent SEC filings of Iterum Therapeutics plc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	8-K	Current Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 05, 2024	8-K	Current Report
Mar 29, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Jan 31, 2024	SC 13G	Major Ownership Report
Jan 30, 2024	8-K	Current Report

Peers (Alternatives to Iterum Therapeutics plc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.44	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

Iterum Therapeutics plc News

Latest updates

Iterum Therapeutics plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	-25.2%	23.00	31.00	27.00	21.00	24.00	25.00	16.00	12.00	-	-
S&GA Expenses	-21.7%	2.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	-	-
R&D Expenses	-25.6%	21.00	28.00	24.00	17.00	21.00	23.00	14.00	11.00	-	-
Interest Expenses	-7.0%	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Income Taxes	-52.9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Earnings Before Taxes	24.3%	-23.59	-31.17	-27.48	-20.45	-24.05	-24.80	-15.68	-12.06	-	-
Net Income	24.4%	-23.64	-31.27	-27.64	-20.58	-24.26	-24.90	-15.75	-12.15	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-33.9%	26.00	40.00	51.00	58.00	67.00	72.00	77.00	84.00	92.00	98.00	106	115	33.00	26.00	32.00	42.00	26.00	51.00	71.00	89.00	98.00
Current Assets	-33.6%	26.00	39.00	48.00	54.00	62.00	67.00	71.00	76.00	83.00	90.00	96.00	104	21.00	12.00	18.00	29.00	12.00	37.00	59.00	77.00	93.00
Cash Equivalents	26.1%	6.00	5.00	14.00	17.00	21.00	20.00	9.00	31.00	27.00	36.00	37.00	67.00	15.00	9.00	12.00	23.00	5.00	29.00	51.00	65.00	45.00
Net PPE	-13.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-10.0%	33.00	36.00	44.00	39.00	39.00	39.00	33.00	35.00	41.00	46.00	59.00	84.00	83.00	82.00	80.00	84.00	52.00	54.00	47.00	38.00	26.00
Current Liabilities	-17.6%	14.00	16.00	11.00	8.00	9.00	8.00	7.00	10.00	13.00	18.00	34.00	44.00	42.00	41.00	41.00	47.00	37.00	37.00	28.00	18.00	12.00
Long Term Debt	-8.1%	11.00	12.00	12.00	11.00	10.00	9.00	9.00	8.00	7.00	6.00	5.00	6.00	22.00	22.00	21.00	19.00	8.00	9.00	11.00	12.00	13.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	2.00	3.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	3.00	2.00	1.00
LT Debt, Non Current	-8.1%	11.00	12.00	12.00	11.00	10.00	9.00	9.00	8.00	7.00	6.00	5.00	6.00	22.00	22.00	21.00	19.00	8.00	9.00	11.00	12.00	13.00
Shareholder's Equity	-286.6%	-6.40	3.00	7.00	19.00	28.00	33.00	44.00	49.00	50.00	52.00	47.00	32.00	51.00	-	-	-	-	-	25.00	52.00	72.00
Retained Earnings	-2.8%	-461	-448	-445	-432	-422	-417	-388	-381	-378	-374	-378	-385	-286	-275	-263	-251	-234	-211	-180	-152	-131
Additional Paid-In Capital	0.6%	455	452	452	452	451	450	431	429	429	425	423	416	236	220	215	209	209	208	204	204	203
Shares Outstanding	-0.6%	13.00	13.00	13.00	13.00	12.00	12.00	12.00	12.00	11.00	10.00	12.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	14.00	-	-	-	37.00	-	-	-	411	-	-	-	14.00	-	-	-	37.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-38.6%	-12,843	-9,265	-7,632	-9,590	-4,265	-4,539	-6,264	-3,405	-2,459	-3,910	-8,341	-1,132	-9,031	-4,417	-13,689	-27,391	-23,053	-25,410	-18,406	-15,053	-25,187
Share Based Compensation	-2.1%	139	142	110	393	457	422	1,984	1,895	1,967	1,512	559	281	126	850	1,186	597	499	561	573	540	412
Cashflow From Investing	3656.4%	13,523	360	4,347	5,106	4,378	3,311	-3,325	9,593	-4,466	4,935	-21,144	-33,920	-	-9.00	-	-	-2.00	25.00	4,988	35,090	28,746
Cashflow From Financing	5790.0%	589	10.00	200	235	433	-	-	-2,251	-1,629	-1,634	-592	86,982	15,127	767	2,710	45,871	-1,034	3,038	10.00	49.00	1,369

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ITRM Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ (39,992)	$ (17,617)	$ (10,712)
General and administrative	(7,476)	(12,766)	(13,825)
Total operating expenses	(47,468)	(30,383)	(24,537)
Operating loss	(47,468)	(30,383)	(24,537)
Interest expense, net	(1,428)	(2,361)	(5,553)
Adjustments to fair value of derivatives	11,056	5,458	(60,964)
Cancellation of share options		(17,350)
Other income, net	82	503	195
Total other expense / (income)	9,710	(13,750)	(66,322)
Loss before income taxes	(37,758)	(44,133)	(90,859)
Income tax expense	(613)	(301)	(705)
Net loss	$ (38,371)	$ (44,434)	$ (91,564)
Net loss per share - basic	$ (2.96)	$ (3.63)	$ (8.41)
Net loss per share - diluted	$ (2.96)	$ (3.63)	$ (8.41)
Weighted average ordinary shares outstanding - basic	12,962,362	12,236,607	10,891,178
Weighted average ordinary shares outstanding - diluted	12,962,362	12,236,607	10,891,178
Statements of Comprehensive Loss
Net loss	$ (38,371)	$ (44,434)	$ (91,564)
Unrealized income / (loss) on marketable securities	351	(350)
Comprehensive loss	$ (38,020)	$ (44,784)	$ (91,564)

ITRM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,071	$ 21,092
Short-term investments	17,859	39,712
Prepaid expenses and other current assets	1,628	1,338
Income taxes receivable	38	302
Total current assets	25,596	62,444
Intangible asset, net		1,719
Property and equipment, net	51	69
Restricted cash	34	34
Other assets	578	2,567
Total assets	26,259	66,833
Current liabilities:
Accounts payable	4,996	2,774
Accrued expenses	7,761	4,346
Derivative liability		196
Other current liabilities	761	1,748
Total current liabilities	13,518	9,064
Long-term debt	11,453	10,094
Royalty-linked notes	7,503	18,372
Other liabilities	188	1,304
Total liabilities	32,662	38,834
Commitments and contingencies (Note 15)
Shareholders' (deficit) / equity
Undesignated preferred shares, $0.01 par value per share: 100,000,000 shares authorized at December 31, 2023 and December 31,2022; no shares issued at December 31, 2023 and December 31, 2022
Ordinary shares, $0.01 par value per share: 80,000,000 shares authorized at December 31, 2022, 13,499,003 shares issued at December 31, 2023; 12,598,641 shares issued at December 31, 2022	135	126
Additional paid-in capital	454,759	451,150
Accumulated deficit	(461,298)	(422,927)
Accumulated other comprehensive gain / (loss)	1	(350)
Total shareholders' (deficit) / equity	(6,403)	27,999
Total liabilities and shareholders' (deficit) / equity	$ 26,259	$ 66,833

About Iterum Therapeutics plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

CEO	Mr. Corey N. Fishman
WEBSITE	iterumtx.com
INDUSTRY	Biotechnology
EMPLOYEES	14

Iterum Therapeutics plc Frequently Asked Questions

What is the ticker symbol for Iterum Therapeutics plc? What does ITRM stand for in stocks?

ITRM is the stock ticker symbol of Iterum Therapeutics plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Iterum Therapeutics plc (ITRM)?

As of Tue Apr 30 2024, market cap of Iterum Therapeutics plc is 25.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITRM stock?

You can check ITRM's fair value in chart for subscribers.

What is the fair value of ITRM stock?

You can check ITRM's fair value in chart for subscribers. The fair value of Iterum Therapeutics plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Iterum Therapeutics plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ITRM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Iterum Therapeutics plc a good stock to buy?

The fair value guage provides a quick view whether ITRM is over valued or under valued. Whether Iterum Therapeutics plc is cheap or expensive depends on the assumptions which impact Iterum Therapeutics plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITRM.

What is Iterum Therapeutics plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, ITRM's PE ratio (Price to Earnings) is -0.65 and Price to Sales (PS) ratio is 683.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITRM PE ratio will change depending on the future growth rate expectations of investors.